Case Summary:                

We are pleased to share the success story of an EB-1A approval. The approval was granted to a clinical researcher from India specializing in the study of inflammatory bowel disease (IBD) and gut-microbiome interaction. At the time of filing, the client was serving as a gastroenterology fellow at a U.S.-based medical institution, conducting translational research aimed at improving outcomes for patients with severe IBD through risk factor identification and novel treatment development.

Advancing Global Understanding of IBD Diagnosis and Management

The client’s research focuses on analyzing Clostridioides difficile infection (CDI), assessing histological predictors in ulcerative colitis, and refining diagnostic approaches for Crohn’s disease versus intestinal tuberculosis. Her findings have provided critical insights for disease monitoring, cost-effective therapies, and preemptive treatment strategies. She has also evaluated the economic impact and clinical value of emerging treatments like fecal microbiota transplantation.

These contributions are being applied globally to improve disease stratification, mitigate relapse risk, and support therapeutic innovation in IBD management.

Research Impact and Global Recognition

In support of the petition, NAILG documented:

• 13 peer-reviewed journal articles (including 9 first-authored papers) and 1 preprint
• 342 citations from researchers across at least 44 countries
• 11 completed peer reviews for high-impact journals such as The Journal of Crohn’s and Colitis and the Journal of Molecular Medicine

At least seven of the client’s papers are among the top 10% most cited in clinical medicine for their publication years. Her work has been cited by leading research institutions across North America, Europe, Asia, and Oceania, underscoring her wide-reaching influence.

Here is a compelling excerpt from one of the recommendation letters that highlights the significance of the client’s contributions:

“[Client’s] research on Clostridioides difficile infection offers a clear direction for shifting treatment standards toward more effective and cost-efficient options like fidaxomicin and fecal microbiota transplantation. Her work continues to influence therapeutic strategies across a range of gastrointestinal conditions and demonstrates the indispensable value of her contributions to the United States.”

Well Positioned to Advance the Proposed Endeavor

In our legal argument, we demonstrated that the client had made original contributions of major significance, was actively engaged in reviewing the work of other experts, and had published extensively in top-tier journals including The Lancet Gastroenterology & Hepatology and Clinical Gastroenterology and Hepatology. Her research addresses global healthcare challenges and contributes to data-driven patient care, especially in complex cases involving immune-mediated gastrointestinal conditions.

Given her active research appointment, publication record, and continued engagement with international collaborators, we established that the client is well-positioned to continue delivering high-impact contributions in the United States.

Approval and Outcome

Despite the issuance of an RFE, this EB1A petition was approved within four months under premium processing. The response to the RFE included strong independent evidence, citation analyses, and expert support letters that confirmed the client’s top-tier standing in the field.

We are proud to have supported this talented clinical researcher and secured her EB-1A approval. NAILG looks forward to her continued contributions in transforming the landscape of gastrointestinal healthcare and IBD treatment.